Medical clinical trial assistant system and method based on virtual reality technology

Abstract

The invention relates to a medical clinical trial auxiliary system and method based on virtual reality technology. The system includes a medical clinical trial hardware system and a medical clinical trial software. The clinical trial hardware system is composed of an interactive integration unit and a data integration unit. The clinical trial software consists of The composition of the application program and data analysis system; the method includes: establishing a trial plan before the newly developed drug enters the clinical trial link; establishing a prediction model for each clinical individual through a machine learning neural network according to the individual behavior and bioelectrical signals of the clinical individual; Clinical individuals are divided into groups to implement drugs, and clinical data are obtained through trials; non-drug effects are eliminated from clinical data, and drug effect data dominated by drug factors are obtained. The invention adopts virtual reality technology to provide clinical trial auxiliary functions for the development of neurological drugs, obtains key data on the effectiveness of clinical drugs, and helps drug developers reduce technical risks in clinical trials.

Description

technical field [0001] The invention belongs to the field of information technology, and relates to a medical clinical trial system, in particular to a medical clinical trial auxiliary system and method based on virtual reality technology. Background technique [0002] In the process of pharmaceutical development, neurological drug development is currently one of the most risky drug development categories for pharmaceutical manufacturers. The process is full of a lot of uncertainties and risks, which often make pharmaceutical companies fail to develop drugs due to unsatisfactory clinical trial data after spending huge sums of money. Compared with the development of drugs for other common diseases, in addition to the foreseeable risks such as the conventional drug mechanism of action and the screening of original drugs, neurological drugs will inevitably have to deal with a large number of additional interferences in the clinical trial process, resulting in inability to obtai...

AI Technical Summary

Problems solved by technology

[0004] Whether the new drug entering the clinical trial can effectively interfere with the neural activity of the test subject, due to the diverse identities and backgrounds of such clinical individuals, may cause a large dispersion of test results, and in the process of horizontal control comparison, due to The highly discrete nature of the data makes it impossible to confirm the final test results in the statistical model, which ultimately leads to the failure of drug development

Images